Tecentriq®

L’association Tecentriq et Avastin de Roche offre un nouvel espoir aux patients atteints d’un cancer du foie à un stade précoce

Annonce ad hoc conformément à l'art. 53LR (COMMUNIQUÉ DE PRESSE) BÂLE, 19-Jan-2023 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY),…

1 year ago

Roche on Tecentriq’s US FDA Priority Review grant: New treatment options are urgently needed in early-stage non-small cell lung cancer

Application is being reviewed under the US FDA’s Real-Time Oncology Review pilot programme Based on results of the Phase III IMpower010…

3 years ago

ASCO20 Virtual Scientific Program: Roche to present new data from clinical trials of approved and investigational medicines across 21 cancer types

First clinical data from tiragolumab, Roche’s novel anti-TIGIT cancer immunotherapy, in combination with Tecentriq® (atezolizumab) in patients with PD-L1-positive metastatic…

4 years ago